Of the parent trial, IHC results for CD3+, CD4+, CD8+, CD45RO+, and CD56+ were available for 219 (87%) patients in the vitamin D group and 153 (92%) patients in the placebo group, for a total of 372 patients (89%) (mean age, 66.5 years; male, 66.7%; esophageal cancer, 9.1%; gastric cancer, 42.8%; small bowel cancer, 0.5%; colorectal cancer, 47.6%), due to lack of tissue samples: no cancer tissue availability, a special tissue subtype such as neuroendocrine tumor, or inappropriate samples during the TMA process (Figure S1). This evidence concerns the gene CD8A and colorectal cancer.